 |
[라포르시안] Daewon Pharmaceutical (CEO Seung-Yeol Baek) announced on the 15th that the potagel suspension made by the governor maintained the No. 1 market share in January following the No. 1 market share in the fourth quarter of last year.
According to Ubist, a drug market research institute, potagel suspension amounted to a total of about 1 billion won in the fourth quarter of last year, accounting for 47% of the market share.
The prescription amount grew by a whopping 50% compared to the previous quarter, the third quarter, and the market share also doubled.
In particular, the market share from 36% in October last year rose to 49% in November, and in December, it reached 56%, more than half of the total market.
In January of this year, the potagel suspension reached 59% of the market share with a prescription amount of 450 million won, and the market share is gradually increasing.
Potagel suspension containing dioctahedral smectide as the main component is an antidiarrheal agent used to relieve acute/chronic diarrhea and pain in the esophagus, stomach, and duodenum.
It acts on the damaged mucous membrane from the esophagus to the intestine to quickly relieve symptoms, prevents the destruction of mucus-producing cells in the small intestine, and protects the intestine by increasing the amount and quality of mucus.
In addition, it removes the main cause of diarrhea by adsorbing and excreting pathogenic bacteria, toxins, viruses, gas produced by abnormal fermentation in the intestine, and bile acids.
Smectite, the main component of potagel suspension, is a natural inorganic substance that is not absorbed by the human body.
In the event of diarrhea accompanied by abdominal pain, it can be safely taken from infants to adults regardless of age. Recently, the product has been renewed in the form of a stick-type pouch that can be easily squeezed, and by applying smart cut technology, you can easily unpack the package by hand without tools such as scissors.
A representative from Daewon Pharmaceutical said, “It is a product that is directly produced by Daewon Pharmaceutical’s new cGMP-level factory with excellent facilities, unlike other products sold by importing finished products.” He said, “We plan to expand investment in machine R&D.”
Reporter Eui-Sik Son [email protected]
<저작권자 © 라포르시안, 무단 전재 및 재배포 금지>